Alnara Pharmaceuticals

Developing orally delivered protein therapeutics for cystic fibrosis patients

Alnara was founded in 2008 to develop orally-delivered, non-systemic enzyme therapeutics that remain active through the gastrointestinal tract. The company's lead product, liprotamase, is a soluble, stable, and non-porcine derived enzyme product for treatment of patients with low digestive enzyme levels due to cystic fibrosis and potentially other diseases. Alnara was acquired by Eli Lilly in 2010.

Acquired by Eli Lilly & Co. in 2010
Year of Investment
Life Sciences
Boston, Massachusetts